Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by YDS Pharmatech
FKSFold: Improving AlphaFold3-Type Predictions of Molecular Glue-Induced Ternary Complexes with Feynman-Kac-Steered Diffusion
Abstract This paper discloses technical details of an early approach we explored for molecular glue induced ternary complex structure prediction using Feynman-Kac (FK) steering in the diffusion modules of AlphaFold3-type models.
FragLlama: Next-fragment prediction for molecular design
Abstract The emergence of ChatGPT has drawn significant attention to Large Language Models (LLMs) due to their impressive performance. While LLMs primarily focus on next token/word prediction, we apply this principle to molecular design by reframing the task as predicting the next token/fragment. We present FragLlama, a large language model trained for molecular design, featuring custom tokens that represent molecular fragments and functional groups.
YDS Pharmatech Launches Data Partner Program with LeadArt Biotechnologies, leveraging Chemoproteomics Data for Enhanced AI Model Development
, /PRNewswire/ -- YDS Pharmatech, a pioneering innovator at a transformative juncture in applying AI and biophysics simulations to drug discovery, is thrilled to announce the launch of its data partner program with its inaugural partner, LeadArt Biotechnologies. This partnership marks a significant step forward in the pursuit of cutting-edge AI architectures tailored for the chemoproteomics sector.
YDS Pharmatech, Inc. CEO to Highlight AI Advancements in Designing New Drug Modalities at Bio Investor Forum on October 17th
, /PRNewswire/ -- YDS Pharmatech, Inc., a pioneering innovator at a transformative juncture in applying AI to drug discovery, announces its participation in this year's Bio Investor Forum. The company's CEO, Dr. Xing Che, is scheduled to present on October 17, 2023, at 4:15 PM in the Franciscan C room on the Ballroom Level. She will delve into the significant strides YDS Pharmatech has made in leveraging the power of AI for designing new therapeutics modalities.
YDS Pharmatech Appoints Dr. Robert Sullivan as Head of Medicinal Chemistry
, /PRNewswire/ -- YDS Pharmatech, a computational drug discovery company specializing in induced proximity, today announced the appointment of Dr. Robert Sullivan as Head of Medicinal Chemistry. With over 20 years of experience in the field, Dr. Sullivan possesses expertise in small molecules, PROTACs, peptides, and oligonucleotides.
YDS Pharmatech's New Generative Diffusion Model Significantly Improves Structure-Based PROTAC Optimization and Ternary Interaction Analysis; Presentation at Drug Discovery Chemistry 2023 Conference
YDS Pharmatech's New Generative Diffusion Model Significantly Improves Structure-Based PROTAC Optimization and Ternary Interaction Analysis; Presentation at Drug Discovery Chemistry 2023 Conference , /PRNewswire/ -- A groundbreaking study by a team of scientists at YDS Pharmatech, Inc.
YDS Pharmatech to Present at Biotech Showcase™ during J.P. Morgan Week 2023 Original
, /PRNewswire/ -- YDS Pharmatech, Inc. ("YDS"), today announced that it is presenting at Biotech Showcase™ 2023. YDS is a techbio startup dedicated to building low-data-dependent AI solutions for drug design. It will present the latest achievements of its innovative biophysics simulation-informed AI platform.
YDS Pharmatech to Present at Biotech Showcase™ during J.P. Morgan Week 2023
YDS Pharmatech to Present at Biotech Showcase™ during J.P. Morgan Week 2023 , /PRNewswire/ -- YDS Pharmatech, Inc. ("YDS"), today announced that it is presenting at Biotech Showcase™ 2023. YDS is a techbio startup dedicated to building low-data-dependent AI solutions for drug design. It will present the latest achievements of its innovative biophysics simulation-informed AI platform.
published in Nature Chemical Biology Original
, /PRNewswire/ -- YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today. The publication was co-authored by Xing Che, Ph.D., founder and CEO of YDS Pharmatech, and by researchers at Tianjin Medical University led by Prof. Heng Zhang. The company helped reveal a new viral protein recognition mechanism, highlighting a promising new target for antiviral drugs.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with YDS
Contact YDS, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack